New study tailors chemo and radiation for pancreatic cancer patients

NCT ID NCT03322995

Recruiting now Disease control Sponsor: Medical College of Wisconsin Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tests an adaptive treatment plan for people with localized pancreatic cancer. Doctors adjust chemotherapy and radiation based on how the tumor responds, aiming to get more patients to successful surgery. The study enrolls 125 adults with resectable or borderline resectable cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: chemotherapy (FOLFIRINOX, gemcitabine) and radiation
What this could lead to: If successful, this approach could help more patients with pancreatic cancer complete treatment and undergo surgery, potentially improving survival.
What could go wrong: This is a phase 2 trial with only 125 participants, so results are preliminary. Pancreatic cancer is aggressive, and the therapy may not work for everyone or may cause significant side effects.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

malignant pancreatic neoplasm pancreatic adenocarcinoma pancreatic ductal adenocarcinoma pancreatic neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PANCREATIC CANCER

Contacts and locations

Locations

Froedtert & the Medical College of Wisconsin
RECRUITING

Milwaukee, Wisconsin, 53226, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.